Sotio

sotio is part of the ppf group, one of the largest investment groups in central and eastern europe. sotio is leading the efforts of ppf group to build a diverse biotechnology portfolio through its own r&d, collaborations, in-licensing, minority investments and m&a. the most advanced program in its portfolio is a proprietary platform of active cellular immunotherapy on the basis of dendritic cells, currently in phase iii international clinical study. sotio includes a team of 370 employees, facilities in europe, the united states, china and russia and in-house capabilities needed for research, clinical development and marketing of novel therapeutics.